Multicenter noninferiority evaluation of hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB line probe assays for detection of rifampin and isoniazid resistance

Journal of Clinical Microbiology

Volumn 54, Issue 6, 2016, Pages 1624-1630

  Nathavitharana, Ruvandhi R ^a   Hillemann, Doris ^b   Schumacher, Samuel G ^c   Schlueter, Birte ^b   Ismail, Nazir ^d   Omar, Shaheed Vally ^d   Sikhondze, Welile ^e   Havumaki, Joshua ^c   Valli, Eloise ^c   Boehme, Catharina ^c   Denkinger, Claudia M ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b RESEARCH CENTER BORSTEL   (Germany)

^c FIND   (Switzerland)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e Ministry of Health   (Swaziland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; HAIN GENOTYPE MTBDRPLUS VERSION 2 ASSAY; HEALTH CARE POLICY; HUMAN; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MYCOBACTERIUM; NIPRO NTM MDRTB DETECTION KIT 2 ASSAY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; GENOTYPING TECHNIQUES; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84969927079     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00251-16     Document Type: Article

References (18)

1. Abate D, Tedla Y, Meressa D, Ameni G. 2014. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis 18:946-951. http://dx.doi.org/10.5588/ijtld.13.0926.
2. Heifets LB, Cangelosi GA. 1999. Drug susceptibility testing of Mycobacterium tuberculosis: A neglected problem at the turn of the century. Int J Tuberc Lung Dis 3:564-581.
3. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, Drobniewski F, Lalvani A. 2007. A systematic review of rapid d iagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11:1-196. http://dx.doi.org/10.3310/hta11030.
4. Small PM, Pai M. 2010. Tuberculosis diagnosis-time for a game change. N Engl J Med 363:1070-1071. http://dx.doi.org/10.1056/NEJMe1008496.
5. Ling DI, Zwerling AA, Pai M. 2008. Rapid diagnosis of drug-resistant TB using line probe assays: From evidence to polic y. Expert Rev Respir Med 2:583-588. http://dx.doi.org/10.1586/17476348.2.5.583.
6. WHO. 2008. WHO policy statement: Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. WHO, Geneva, Switzerland. http://www.who.int/tb/laboratory/line -probe-assays/en/.
7. Ling DI, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis : A meta-analysis. Eur Respir J 32:1165-1174. http://dx.doi.org/10.1183/09031936.00061808.
8. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. 2012. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF a ssay. J Clin Microbiol 50:3712-3716. http://dx.doi.org/10.1128/JCM.01958-12.
9. Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N. 2012. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 50:1264-1269. http://dx.doi.org/10.1128/JCM.05903-11.
10. Mitarai S Kato S Ogata H Aono A Chikamatsu K Mizuno K Toyota E Sejimo A Suzuki K Yoshida S Saito T Moriya A Fujita A Sato S Matsumoto T Ano H Suetake T Kondo Y Kirikae T Mori T. 20 1 2 Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis J Clin Microbiol 50 884-890 http://dx.doi.org/10.112 8/JCM.05638-11.
11. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: Chall enging the gold standard. J Clin Microbiol 51:2633-2640. http://dx.doi.org/10.1128/JCM.00553-13.
12. FDA. 2010. Guidance for industry: Non-inferiority clinical trials. FDA, Washington, DC. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf.
13. Rothmann MD, Wiens BL, Chan ISF. 2011. Design and analysis of non-inferiority trials. Chapman and Hall/CRC Press, Boca Raton, FL.
14. Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, de Jong BC. 2015. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuber c Lung Dis 19:185-190. http://dx.doi.org/10.5588/ijtld.14.0651.
15. Deepa D, Achanta S, Jaju J, Rao K, Samyukta R, Claassens M, Kumar AM, Vishnu PH. 2013. The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India. PLoS One 8:e76189. http://dx.doi.org/10.1371/journal.pone.0076189.
16. Niehaus AJ , Mlisana K, Gandhi NR, Mathema B, Brust JC. 2015. High prevalence of inhA promoter mutations among patients with drugresistant Tuberculosis in KwaZulu-Natal, South Africa. PLoS One 10: E0135003. http://dx.do i.org/10.1371/journal.pone.0135003.
17. Hillemann D, Rusch-Gerdes S, Richter E. 2007. Evaluation of the Geno-TypeMTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45:2635-2640. http://dx.doi.org/10.1128/JCM.00521-07.
18. WHO. 2015. Global tuberculosis report 2015. WHO, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.